• Journal Archive /
• 2019 /
• №4

Vitaprost Forte in the treament of patients with benign prostatic hyperplasia: pathogenetic basics and clinical results

DOI: https://dx.doi.org/10.18565/urology.2019.4.141-147

I.V. Kuz’min

Department of Urology of FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia, Saint Petersburg, Russia

About the Autors

Corresponding author: I.V. Kuz’min – MD, professor of the Department of Urology of FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia, Saint Petersburg, Russia; e-mail: kuzminigor@mail.ru

Similar Articles

• Combination of α1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study
• Possibilities of using sildenafil in patients with cardiovascular comorbidities who underwent transurethral resection of the prostate
• The current status of surgical treatment of benign prostatic hyperplasia with volume over 80 сс.
• The role of angiotensin-converting enzyme and angiotensin ii receptors of the second type in the pathogenesis of proliferative diseases of the prostate
• Holmium laser enucleation of the prostate (HOLEP) for small, large and giant prostatic hyperplasia. Practice guidelines. Experience of more than 450 surgeries